Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
X Du, Y Shao, HF Qin, YH Tai, HJ Gao - Thoracic cancer, 2018 - Wiley Online Library
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically
expressed in the nervous system during embryogenesis, but its expression decreases …
expressed in the nervous system during embryogenesis, but its expression decreases …
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
BJ Solomon, B Besse, TM Bauer, E Felip… - The Lancet …, 2018 - thelancet.com
Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity …
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity …
[HTML][HTML] Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer
JJ Lin, VW Zhu, S Yoda, BY Yeap… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung
cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs) …
cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs) …
Leptomeningeal metastases in non-small-cell lung cancer
H Cheng, R Perez-Soler - The Lancet Oncology, 2018 - thelancet.com
Leptomeningeal metastasis is a complication of advanced non-small-cell lung cancer
(NSCLC). Diagnosis and monitoring of leptomeningeal metastasis are challenging, and are …
(NSCLC). Diagnosis and monitoring of leptomeningeal metastasis are challenging, and are …
Ensartinib (X-396) in ALK-positive non–small cell lung cancer: results from a first-in-human phase I/II, multicenter study
L Horn, JR Infante, KL Reckamp… - Clinical Cancer …, 2018 - AACR
Purpose: Evaluate safety and determine the recommended phase II dose (RP2D) of
ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor …
ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor …
Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non–small-cell lung cancer and brain metastases in two clinical trials
DR Camidge, DW Kim, M Tiseo, CJ Langer… - Journal of Clinical …, 2018 - ascopubs.org
Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene (ALK)-
rearranged non–small-cell lung cancer (ALK-positive NSCLC), initial disease progression …
rearranged non–small-cell lung cancer (ALK-positive NSCLC), initial disease progression …
Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA
I Dagogo-Jack, AR Brannon, LA Ferris… - JCO precision …, 2018 - ascopubs.org
Purpose ALK (anaplastic lymphoma kinase) rearrangements predict for sensitivity to ALK
tyrosine kinase inhibitors (TKIs); however, responses to ALK TKIs are generally short lived …
tyrosine kinase inhibitors (TKIs); however, responses to ALK TKIs are generally short lived …
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
M Reck - Immunotherapy, 2018 - Future Medicine
This review describes trials evaluating the monoclonal antibody pembrolizumab (an
immunotherapy that blocks the interaction between programmed death-1 and programmed …
immunotherapy that blocks the interaction between programmed death-1 and programmed …
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
A Sgambato, F Casaluce, P Maione… - Expert review of …, 2018 - Taylor & Francis
Introduction: Anaplastic lymphoma kinase (ALK) and ROS1 rearrangements define
important molecular subgroups of advanced non-small cell lung cancer (NSCLC). The …
important molecular subgroups of advanced non-small cell lung cancer (NSCLC). The …